Metrics as of 10/15/2026, 07:23 AM (Berlin time), refresh in progress.
CytomX Therapeutics Stock
CytomX Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Sean A. McCarthy
- Employees
- 69
- Market cap
- $486 M
- IPO
- 08/10/2015
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several…
CytomX Therapeutics stock: price history
1D
-4.3%
1W
-12.5%
1M
-30.3%
6M
-51.1%
YTD
-47.7%
1Y
-34.8%
2Y
+104.6%
5Y
-56.6%
10Y
-82.6%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~112% stronger price swings than usual
Ask the agents about CytomX Therapeutics
Analyst assessment of CytomX Therapeutics
PRICE TARGET LOW
US$6.00
CONSENSUS
US$8.50
MEDIAN
US$8.50
PRICE TARGET HIGH
US$11.00
0
STRONG BUY
17
BUY
4
HOLD
0
SELL
0
STRONG SELL
21
TOTAL · Buy
As of: 13/08/2026
CytomX Therapeutics stock metrics
P/E
-4.96
P/B
1.62
EV/EBITDA
-6.04
RETURN ON EQUITY
-6.8%
NET MARGIN
-1,457.4%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
81.0%
FLOAT SHARES
176,524,774
AVG. DAILY VOLUME (30D)
3,908,483
Insider transactions (SEC)
Carvajal Alejandra
Ogden Christopher
Institutional holders
Comparable stocks
Frequently asked questions about CytomX Therapeutics stock
What does CytomX Therapeutics do?
CytomX Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Sean A. McCarthy, the company employs around 69 people.
The IPO was on 08/10/2015; the stock trades on NASDAQ under the ticker CTMX.
What do analysts say about CytomX Therapeutics stock?
21 analysts rate the stock, the consensus is Buy (as of 13/08/2026).
The average price target is US$8.50, ranging from US$6.00 to US$11.00, with a median of US$8.50.
This is an external assessment, not a statement by Market Jury.
When does CytomX Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 112% stronger than usual.
Does CytomX Therapeutics pay a dividend?
No, CytomX Therapeutics currently does not pay a dividend.
Which stocks are comparable to CytomX Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get CytomX Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess CytomX Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.